The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining

Trends in Neurosciences

Volumn 32, Issue 1, 2009, Pages 2-8

  Gonon, Francois ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CITALOPRAM; CLONIDINE; DESIPRAMINE; DOPAMINE; PSYCHOSTIMULANT AGENT; RACLOPRIDE;

ARTICLE; ATTENTION DEFICIT DISORDER; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; LEARNING; MOLECULAR GENETICS; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REWARD;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; HUMANS; PSYCHOLOGICAL THEORY;

EID: 58149510315     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2008.09.010     Document Type: Article

References (83)

1. Schonwald A. Update: attention deficit/hyperactivity disorder in the primary care office. Curr. Opin. Pediatr. 17 (2005) 265-274
2. Froehlich T.E., et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch. Pediatr. Adolesc. Med. 161 (2007) 857-864
3. Swanson J.M., et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol. Rev. 17 (2007) 39-59
4. Volkow N.D., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21 (2001) RC121
5. Spencer T.J., et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol. Psychiatry 57 (2005) 1293-1300
6. Volkow N.D., et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 34 (2007) 1182-1190
7. Iversen S.D., and Iversen L.L. Dopamine: 50 years in perspective. Trends Neurosci. 30 (2007) 188-193
8. Volkow N.D., et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43 (2002) 181-187
9. Rosa-Neto P., et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 25 (2005) 868-876
10. Volkow N.D., et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 64 (2007) 932-940
11. Gambarana C., et al. A chronic stress that impairs reactivity in rats also decreases dopaminergic transmission in the nucleus accumbens: a microdialysis study. J. Neurochem. 72 (1999) 2039-2046
12. Hooks M.S., et al. Individual differences in basal and cocaine-stimulated extracellular dopamine in the nucleus accumbens using quantitative microdialysis. Brain Res. 587 (1992) 306-312
13. Carboni E., et al. Effect of amphetamine, cocaine and depolarization by high potassium on extracellular dopamine in the nucleus accumbens shell of SHR rats. An in vivo microdyalisis study. Neurosci. Biobehav. Rev 27 (2003) 653-659
14. Casey B.J., et al. New potential leads in the biology and treatment of attention deficit-hyperactivity disorder. Curr. Opin. Neurol. 20 (2007) 119-124
15. Heiser P., et al. Molecular genetic aspects of attention-deficit/hyperactivity disorder. Neurosci. Biobehav. Rev. 28 (2004) 625-641
16. 4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 64 (2007) 921-931
17. Brookes K., et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol. Psychiatry 11 (2006) 934-953
18. Maher B.S., et al. Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr. Genet. 12 (2002) 207-215
19. Neuman R.J., et al. Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biol. Psychiatry 61 (2007) 1320-1328
20. Rapoport J.L., et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 199 (1978) 560-563
21. Rapoport J.L., and Inoff-Germain G. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002. J. Atten. Disord. 6 (2002) S57-S60
22. Wilens T.E., et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 47 (2008) 21-31
23. Pliszka S.R. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1385-1390
24. Javoy-Agid F., et al. Distribution of monoaminergic, cholinergic, and GABAergic markers in the human cerebral cortex. Neuroscience 29 (1989) 251-259
25. Moron J.A., et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22 (2002) 389-395
26. Bymaster F.P., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
27. Berridge C.W., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry 60 (2006) 1111-1120
28. Overtoom C.C., et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behav. Brain Res. 145 (2003) 7-15
29. Mick E., and Faraone S.V. Genetics of attention deficit hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. 17 (2008) 261-284
30. Van der Kooij M.A., and Glennon J.C. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 31 (2007) 597-618
31. Castaneda E., et al. Dopamine depletion in neonatal rats: effects on behavior and striatal dopamine release assessed by intracerebral microdialysis during adulthood. Brain Res. 508 (1990) 30-39
32. Jones S.R., et al. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4029-4034
33. Gainetdinov R.R., et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283 (1999) 397-401
34. Davids E., et al. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J. Pharmacol. Exp. Ther. 301 (2002) 1097-1102
35. Sagvolden T., et al. Rodent models of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1239-1247
36. Sagvolden T., and Xu T. l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav. Brain Funct. 4 (2008) 3
37. Sagvolden T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav. Brain Funct. 2 (2006) 41
38. Ferguson S.A., and Cada A.M. A longitudinal study of short- and long-term activity levels in male and female spontaneously hypertensive, Wistar-Kyoto, and Sprague-Dawley rats. Behav. Neurosci. 117 (2003) 271-282
39. Van den Bergh F.S., et al. Spontaneously hypertensive rats do not predict symptoms of attention-deficit hyperactivity disorder. Pharmacol. Biochem. Behav. 83 (2006) 380-390
40. Ferguson S.A., et al. Baseline behavior, but not sensitivity to stimulant drugs, differs among spontaneously hypertensive, Wistar-Kyoto, and Sprague-Dawley rat strains. Neurotoxicol. Teratol. 29 (2007) 547-561
41. 3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of Attention-Deficit Hyperactivity Disorder. Behav. Brain Res. 94 (1998) 163-171
42. Ferguson S.A., et al. In vivo basal and amphetamine-induced striatal dopamine and metabolite levels are similar in the spontaneously hypertensive, Wistar-Kyoto and Sprague-Dawley male rats. Physiol. Behav 80 (2003) 109-114
43. Valera E.M., et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry 61 (2007) 1361-1369
44. Castellanos F.X., et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 288 (2002) 1740-1748
45. Dickstein S.G., et al. The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J. Child Psychol. Psychiatry 47 (2006) 1051-1062
46. Schultz W. Behavioral theories and the neurophysiology of reward. Annu. Rev. Psychol. 57 (2006) 87-115
47. Volkow N.D., and Swanson J.M. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood?. Am. J. Psychiatry 165 (2008) 553-555
48. Salamone J.D. Functions of mesolimbic dopamine: changing concepts and shifting paradigms. Psychopharmacology (Berl.) 191 (2007) 389
49. Le Moal M., and Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev. 71 (1991) 155-234
50. Berridge K.C. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl.) 191 (2007) 391-431
51. Di Chiara G., and Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr. Opin. Pharmacol. 7 (2007) 69-76
52. Salamone J.D., et al. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl.) 191 (2007) 461-482
53. Koob G.F., and Le Moal M. Addiction and the Brain Antireward System. Annu. Rev. Psychol. 59 (2008) 29-53
54. Tindell A.J., et al. Ventral pallidum firing codes hedonic reward: when a bad taste turns good. J. Neurophysiol. 96 (2006) 2399-2409
55. Rushworth M.F., and Behrens T.E. Choice, uncertainty and value in prefrontal and cingulate cortex. Nat. Neurosci. 11 (2008) 389-397
56. Morris G., et al. Midbrain dopamine neurons encode decisions for future action. Nat. Neurosci. 9 (2006) 1057-1063
57. Hille B. G protein-coupled mechanisms and nervous signaling. Neuron 9 (1992) 187-195
58. Benoit-Marand M., et al. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J. Neurosci. 21 (2001) 9134-9141
59. Beckstead M.J., et al. Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron 42 (2004) 939-946
60. Lavin A., et al. Mesocortical dopamine neurons operate in distinct temporal domains using multimodal signaling. J. Neurosci. 25 (2005) 5013-5023
61. Lapish C.C., et al. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology (Berl.) 191 (2007) 609-625
62. Lenoir M., et al. Intense sweetness surpasses cocaine reward. PLoS One 2 (2007) e698
63. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. 8 (2005) 1442-1444
64. Cannon C.M., and Palmiter R.D. Reward without dopamine. J. Neurosci. 23 (2003) 10827-10831
65. Robinson S., et al. Distinguishing whether dopamine regulates liking, wanting, and/or learning about rewards. Behav. Neurosci. 119 (2005) 5-15
66. Cagniard B., et al. Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 31 (2006) 1362-1370
67. Doya K. Modulators of decision making. Nat. Neurosci. 11 (2008) 410-416
68. Palmiter R.D. Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice. Ann. N. Y. Acad. Sci. 1129 (2008) 35-46
69. Evans A.H., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 59 (2006) 852-858
70. Luman M., et al. The impact of reinforcement contingencies on AD/HD: a review and theoretical appraisal. Clin. Psychol. Rev. 25 (2005) 183-213
71. Scheres A., et al. Temporal and probabilistic discounting of rewards in children and adolescents: effects of age and ADHD symptoms. Neuropsychologia 44 (2006) 2092-2103
72. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 56 (1999) 1073-1086
73. Barkley R.A., et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J. Child Psychol. Psychiatry 45 (2004) 195-211
74. Barbaresi W.J., et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J. Dev. Behav. Pediatr. 28 (2007) 265-273
75. Molina B.S., et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J. Am. Acad. Child Adolesc. Psychiatry 46 (2007) 1028-1040
76. Barkley R.A., et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111 (2003) 97-109
77. Biederman J., et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am. J. Psychiatry 165 (2008) 597-603
78. Loe I.M., and Feldman H.M. Academic and educational outcomes of children with ADHD. J. Pediatr. Psychol. 32 (2007) 643-654
79. The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113 (2004) 762-769
80. Barbaresi W.J., et al. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J. Dev. Behav. Pediatr. 28 (2007) 274-287
81. Shaw P., et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19649-19654
82. Schmitz M.F., et al. Social representation of a-Attention Deficit/Hyperactivity Disorder. Cult. Psychol. 9 (2003) 383-406
83. Chronis A.M., et al. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Clin. Psychol. Rev. 26 (2006) 486-502